ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)AA

ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)

19.45USDD
+0.40+2.10%
As of today at 20:00 GMT
USD
No trades
See on Supercharts

Key facts today


A lead plaintiff deadline of June 3, 2025, has been set for AbbVie (ABBV) shareholders involved in a lawsuit over undisclosed facts about AbbVie's interest in acquiring Cerevel.
AbbVie is pushing for U.S. tax code changes to boost domestic production amid ongoing Congressional talks on tax reforms that may benefit the pharmaceutical industry.
Analyze the impactAnalyze the impact
Market capitalization
‪331.06 B‬USD
‪3.76 B‬USD
‪50.04 B‬USD
Beta (1Y)
0.04

About AbbVie Inc.


CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
ARBCOM4603M9
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Performance
‪−4%‬
‪0%‬
‪4%‬
‪8%‬
‪12%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−5.00 B‬‬
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Debt
Free cash flow
Cash & equivalents

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
4ABC
ABBVIE 15/25
Yield to maturity
8.35%
Maturity date
May 14, 2025
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
7.83%
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
7.77%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
7.67%
Maturity date
Oct 1, 2042
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
7.22%
Maturity date
Mar 15, 2035
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
6.26%
Maturity date
Nov 21, 2049
US287YAW9
ABBVIE 16/46
Yield to maturity
6.13%
Maturity date
May 14, 2046
ABBV4036937
AbbVie Inc. 4.4% 06-NOV-2042
Yield to maturity
6.11%
Maturity date
Nov 6, 2042
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
6.05%
Maturity date
Nov 14, 2048
ABBV5068390
AbbVie Inc. 4.75% 15-MAR-2045
Yield to maturity
6.04%
Maturity date
Mar 15, 2045
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
6.03%
Maturity date
Oct 1, 2042

See all ABBVD bonds